es
Feedback

¡No caigas en manos de tramposos! Telemetrio encuentra y marca estos canales 👉 Si quieres ver la etiqueta, suscríbete

JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)

Ir al canal en Telegram

All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

Mostrar más

📈 Análisis del canal de Telegram JAMA (Journal of the American Medical Association)

El canal JAMA (Journal of the American Medical Association) (@jamaupdates) en el segmento lingüístico de Inglés es un actor destacado. Actualmente la comunidad reúne a 17 069 suscriptores, ocupando la posición 1 455 en la categoría Medicina y el puesto 2 173 en la región EEUU.

📊 Métricas de audiencia y dinámica

Desde su creación el невідомо, el proyecto ha mostrado un crecimiento acelerado, reuniendo a 17 069 suscriptores.

Según los últimos datos del 16 noviembre, 2026, el canal mantiene una actividad estable. En los últimos 30 días la variación de miembros fue de 371, y en las últimas 24 horas de 13, conservando un alto alcance.

  • Estado de verificación: No verificado
  • Tasa de interacción (ER): El promedio de interacción de la audiencia es 4.24%. Durante las primeras 24 horas tras publicar, el contenido suele obtener 1.89% de reacciones respecto al total de suscriptores.
  • Alcance de las publicaciones: Cada publicación recibe en promedio 723 visualizaciones. En el primer día suele acumular 323 visualizaciones.
  • Reacciones e interacción: La audiencia responde de forma activa: el promedio de reacciones por publicación es 1.
  • Intereses temáticos: El contenido se centra en temas clave como patient, disease, treatment, drug, guideline.

📝 Descripción y política de contenido

El autor describe el recurso como un espacio para expresar opiniones subjetivas:
“All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

Gracias a la alta frecuencia de actualizaciones (últimos datos recibidos el 17 noviembre, 2026), el canal mantiene la vigencia y un amplio alcance. La analítica demuestra que la audiencia interactúa activamente con el contenido, lo que lo convierte en un punto de referencia dentro de la categoría Medicina.

17 069
Suscriptores
+1324 horas
+967 días
+37130 días
Atraer Suscriptores
nov '26
noviembre '26
+283
en 1 canales
octubre '26
+291
en 0 canales
Get PRO
septiembre '26
+301
en 0 canales
Get PRO
agosto '26
+361
en 0 canales
Get PRO
julio '26
+440
en 0 canales
Get PRO
junio '26
+422
en 1 canales
Get PRO
mayo '26
+584
en 0 canales
Get PRO
abril '26
+437
en 0 canales
Get PRO
marzo '26
+217
en 0 canales
Get PRO
febrero '26
+247
en 0 canales
Get PRO
enero '26
+321
en 0 canales
Get PRO
diciembre '25
+277
en 0 canales
Get PRO
noviembre '25
+366
en 2 canales
Get PRO
octubre '25
+164
en 0 canales
Get PRO
septiembre '25
+12
en 0 canales
Get PRO
agosto '25
+29
en 0 canales
Get PRO
julio '25
+30
en 0 canales
Get PRO
junio '25
+17
en 0 canales
Get PRO
mayo '25
+9
en 0 canales
Get PRO
abril '25
+5
en 0 canales
Get PRO
marzo '25
+17
en 0 canales
Get PRO
febrero '25
+12
en 0 canales
Get PRO
enero '25
+18
en 1 canales
Get PRO
diciembre '24
+237
en 0 canales
Get PRO
noviembre '24
+1 122
en 0 canales
Get PRO
octubre '24
+1 120
en 0 canales
Get PRO
septiembre '24
+1 527
en 1 canales
Get PRO
agosto '24
+1 128
en 1 canales
Get PRO
julio '24
+1 216
en 0 canales
Get PRO
junio '24
+781
en 1 canales
Get PRO
mayo '24
+797
en 1 canales
Get PRO
abril '24
+808
en 1 canales
Get PRO
marzo '24
+821
en 2 canales
Get PRO
febrero '24
+753
en 1 canales
Get PRO
enero '24
+768
en 0 canales
Get PRO
diciembre '23
+716
en 1 canales
Get PRO
noviembre '23
+96
en 1 canales
Get PRO
octubre '23
+86
en 0 canales
Get PRO
septiembre '23
+73
en 0 canales
Get PRO
agosto '23
+90
en 0 canales
Get PRO
julio '23
+107
en 0 canales
Get PRO
junio '23
+105
en 0 canales
Get PRO
mayo '23
+169
en 0 canales
Get PRO
abril '23
+128
en 0 canales
Get PRO
marzo '23
+84
en 0 canales
Get PRO
febrero '23
+75
en 0 canales
Get PRO
enero '23
+71
en 0 canales
Get PRO
diciembre '22
+74
en 0 canales
Get PRO
noviembre '22
+149
en 0 canales
Get PRO
octubre '22
+90
en 0 canales
Get PRO
septiembre '22
+138
en 0 canales
Get PRO
agosto '22
+77
en 0 canales
Get PRO
julio '22
+50
en 0 canales
Get PRO
junio '22
+96
en 0 canales
Get PRO
mayo '22
+75
en 0 canales
Get PRO
abril '22
+80
en 0 canales
Get PRO
marzo '22
+65
en 0 canales
Get PRO
febrero '22
+26
en 0 canales
Get PRO
enero '22
+56
en 0 canales
Get PRO
diciembre '21
+44
en 0 canales
Get PRO
noviembre '21
+39
en 0 canales
Get PRO
octubre '21
+61
en 0 canales
Get PRO
septiembre '21
+66
en 0 canales
Get PRO
agosto '21
+65
en 0 canales
Get PRO
julio '21
+96
en 0 canales
Get PRO
junio '21
+120
en 0 canales
Get PRO
mayo '21
+130
en 0 canales
Get PRO
abril '21
+812
en 0 canales
Fecha
Crecimiento de Suscriptores
Menciones
Canales
17 noviembre+1
16 noviembre+14
15 noviembre+19
14 noviembre+10
13 noviembre+15
12 noviembre+5
11 noviembre+17
10 noviembre+21
09 noviembre+4
08 noviembre+12
07 noviembre+23
06 noviembre+2
05 noviembre+17
04 noviembre+17
03 noviembre+22
02 noviembre+76
01 noviembre+8
Publicaciones del Canal
Blood Conservation and Choice in Surgical Transfusion https://jamanetwork.com/journals/jama/fullarticle/2856799 This Viewpoint discusses blood conservation and surgical transfusion, including patient blood management and bloodless medicine and surgery, among patients who refuse blood.

2
Alcohol Consumption During Pregnancy in the US—Reply https://jamanetwork.com/journals/jama/fullarticle/2856800 In Reply We thank Dr Fan and colleagues for their thoughtful letter and for engaging with our study, which reported an increasing trend in alcohol consumption during pregnancy in the US over the past 2 decades. As discussed by the authors, our descriptive results indicate that older maternal age and tobacco use were both notable correlates of any alcohol use, raising questions about overlapping exposure patterns and potential synergistic effects. While our study was designed to assess population-level trends and does not address etiologic aims directly, we are encouraged that the findings have raised other substantive research questions that could have important implications for prevention and practice.
248
3
Alcohol Consumption During Pregnancy in the US https://jamanetwork.com/journals/jama/fullarticle/2856801 To the Editor The Research Letter by Dr Bruzelius and colleagues documents increased prevalence of alcohol use among pregnant women in the US from 2011 to 2024, particularly among those with older maternal age (35-49 years; 18.2%) and tobacco use (26.3%). Among pregnant women reporting any alcohol use, 68.1% of those who used tobacco also reported binge or heavy drinking, compared with 31.3% of people who did not use tobacco, suggesting a particularly high-risk subgroup that warrants further investigation.
207
4
GLP-1 Utilization After Withdrawal of Medicaid Coverage for Weight Loss https://jamanetwork.com/journals/jama/fullarticle/2856802 This cross-sectional study uses data from Medicaid State Drug Utilization Data to examine associations of coverage withdrawal with Medicaid beneficiaries’ utilization of weight loss–approved glucagon-like peptide-1s.
163
5
Absolute Risk of Progression to Cognitive Impairment Based on Plasma p-Tau217, Age, Sex, and APOE ε4 https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722 This cohort study examines data from the Mayo Clinic Study of Aging and Alzheimer’s Disease Neuroimaging Initiative to determine the 5- and 10-year absolute risks of mild cognitive impairment and dementia among individuals who are biomarker positive and cognitively unimpaired.
174
6
Agent Orange Exposure and Parkinson Disease Among US Veterans https://jamanetwork.com/journals/jamaneurology/fullarticle/2856723 This cohort study investigates the association between Agent Orange and risk of incident Parkinson disease diagnosis among US veterans.
167
7
Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure https://jamanetwork.com/journals/jamaneurology/fullarticle/2856724 This cross-sectional study describes how geographic availability of the minimum health care infrastructure required for subcutaneous therapy for Alzheimer disease treatment varies by age and location across the US.
169
8
Intraocular Hemorrhage After Digital Subtraction Myelography https://jamanetwork.com/journals/jamaneurology/fullarticle/2856725 This case report describes a young adult patient with intraretinal hemorrhages in both eyes resulting in reduction of visual acuity in the left eye.
155
9
Agent Orange and Parkinson Disease—The War Ended, the Exposure Did Not https://jamanetwork.com/journals/jamaneurology/fullarticle/2856726 Agent Orange was a defoliant widely used by the US during the Vietnam War to uncover the positions of North Vietnamese soldiers. The weed killer was a 50:50 mixture of the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) along with small amounts of a potent carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a by-product of the manufacturing process. From 1962 to 1971, the US sprayed at least 75 million liters (20 million gallons) of defoliants over Vietnam and more over Cambodia, Laos, Thailand, South Korea, and possibly Guam, Panama, and even around military bases in the US.
160
10
HEPA Filtration in Care Homes—Distinguishing Implementation From Intervention Failure https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856318 To the Editor Hay et al should be commended for conducting one of the first large pragmatic trials addressing an important and clinically relevant infection-prevention strategy in a highly vulnerable population. However, I believe that several aspects of this study warrant further consideration.
230
11
Evaluation of Identified Serious Risks for Drugs and Biologics Using Surveillance Systems https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856319 This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
252
12
Value Judgments in Comparing Dialysis Facility Performance https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856321 In 2025, the Centers for Medicare & Medicaid Services (CMS) stopped collecting information about race and ethnicity in the dialysis quality measurement system. Koukounas and colleagues in this issue of JAMA Internal Medicine consider how this change might impact comparisons among dialysis facilities. Using national data, they estimated standardized mortality ratios (SMRs) for these facilities, contrasting the results from risk-adjustment models that either include or exclude race and ethnicity. They find that dialysis facilities that serve more socially disadvantaged patients have better SMRs when the model does not adjust for race and ethnicity.
272
13
Pediatric Obesity Pharmacotherapy https://jamanetwork.com/journals/jama/fullarticle/2856798 In the current issue of JAMA, Dr Kelly and colleagues present results from SURMOUNT-ADOLESCENTS, a clinical trial of tirzepatide among adolescents with obesity. The results are impressive: mean body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) decreased by 18.5% with tirzepatide compared with a 0.5% increase with placebo, a treatment difference of 19 percentage points at 72 weeks. Nearly half of tirzepatide-treated participants achieved a BMI reduction of at least 20%, and 53.5% of tirzepatide-treated participants achieved a BMI below the 95th percentile at week 72, compared with 7.1% receiving placebo. As evidence supporting antiobesity medications continues to mount, the question is increasingly not whether pharmacotherapy has a role in pediatric obesity treatment, but which medications should be used for which patients and under what circumstances.
425
14
FDA Approves Novel Treatment for Chronic Hepatitis B https://jamanetwork.com/journals/jama/fullarticle/2856883 The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection.
753
15
Updated Guidance Released for Type 2 Diabetes Care https://jamanetwork.com/journals/jama/fullarticle/2856884 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released a joint consensus statement offering updated clinical guidance for type 2 diabetes.
716
16
Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence Risk https://jamanetwork.com/journals/jama/fullarticle/2856885 A personalized messenger RNA (mRNA) cancer vaccine significantly lowered the risk of disease recurrence or death in patients with high-risk melanoma, a phase 3 trial found.
708
17
Why Do COVID-19 Shots Trigger a Fever for Some? https://jamanetwork.com/journals/jama/fullarticle/2856877 This Medical News article discusses a study that linked the gut microbiome to fever after COVID-19 vaccination.
660
18
Salt Substitutes Come to the Table https://jamanetwork.com/journals/jama/fullarticle/2856876 This Medical News article discusses efforts to increase the use of potassium-enriched salt substitutes to lower sodium intake and prevent and manage hypertension.
601
19
JAMA Editors' Summary Podcast November 13, 2026 https://jamanetwork.com/journals/jama/fullarticle/2856887 Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
570
20
US Health Insurance Coverage Declines https://jamanetwork.com/journals/jama/fullarticle/2856886 US health insurance coverage and access are in decline after 15 years of expansion, according to a 2026 survey from the Commonwealth Fund.
538